Roche-Genentech reach $47bn deal

After more than 8 months of negotiation, it has finally come to fruition. Genentech’s independent directors have granted their blessing for the transaction to push through with the new $95/share or $46.8bn deal.  The Swiss drugmaker now takes the remaining 44% it doesn’t already own.  Through the elimination of duplications, the two companies expect to have cost savings of up to $850m a year before taxes.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s